Intensification of infliximab therapy in Crohn's disease: Efficacy and safety

Journal of Crohn's and Colitis

Volumn 6, Issue 1, 2012, Pages 62-67

  Chaparro, M ^a   Martinez Montiel P ^b   Van Domselaar, M ^c   Bermejo, F ^d   Perez Calle J L ^e   Casis, B ^b   Román, A López San ^c   Algaba, A ^d   Mate J ^a   Gisbert, J P ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^e HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Crohn's disease; Dose escalation; Infliximab; Intensification; Loss of response

Indexed keywords

INFLIXIMAB;

ADULT; AGED; ARTICLE; CROHN DISEASE; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HEALTH SURVEY; HERPES ZOSTER; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84855910403     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.07.005     Document Type: Article

References (21)

1. Panes J., Gomollon F., Taxonera C., Hinojosa J., Clofent J., Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007, 67:2511-2537.
2. Rutgeerts P., Van Assche G., Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment. Pharmacol. Ther. 2006, 23:451-463.
3. Clark M., Colombel J.F., Feagan B.C., Fedorak R.N., Hanauer S.B., Kamm M.A., et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology 2007, 133:312-339.
4. Lichtenstein G.R., Abreu M.T., Cohen R., Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:935-939.
5. Regueiro M., Siemanowski B., Kip K.E., Plevy S. Infliximab dose intensification in Crohn's disease. Inflamm. Bowel Dis. 2007, 13:1093-1099.
6. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
7. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N. Engl. J. Med. 2004, 350:876-885.
8. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126:402-413.
9. Rutgeerts P., D'Haens G., Targan S., Vasiliauskas E., Hanauer S.B., Present D.H., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
10. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 2009, 104:760-767.
11. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin. Gastroenterol. Hepatol. 2006, 4:1248-1254.
12. Hanauer S.B., Wagner C.L., Bala M., Mayer L., Travers S., Diamond R.H., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2004, 2:542-553.
13. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Furst D., Weisman M.H., et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004, 50:1051-1065.
14. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005, 366:1367-1374.
15. St Clair E.W., Wagner C.L., Fasanmade A.A., Wang B., Schaible T., Kavanaugh A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002, 46:1451-1459.
16. Harvey R.F., Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1980, 1:514.
17. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 1999, 340:1398-1405.
18. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997, 337:1029-1035.
19. Schnitzler F., Fidder H., Ferrante M., Noman M., Arijs I., Van Assche G., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
20. Hyams J., Crandall W., Kugathasan S., Griffiths A., Olson A., Johanns J., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007, 132:863-873. quiz 1165-1166.
21. Baert F., Noman M., Vermeire S., Van Assche G., D'Haens G., Carbonez A., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 2003, 348:601-608.